TRALI - new challenges for histocompatibility and immunogenetics in transfusion medicine

Tissue Antigens

Volumn 78, Issue 1, 2011, Pages 1-7

  Flesch, Brigitte K ^a   Petershofen, E K ^b   Bux, J ^a  

^a German Red Cross Blood Service West   (Germany)

^b Institute Springe   (Germany)

Author keywords

Blood product transfusion; Human leukocyte antigen class I and class II; Human neutrophil antigens; Leukocyte antibodies; Transfusion related acute lung injury

Indexed keywords

ANTIGEN; ANTIGEN HNA 3A; HLA ANTIBODY; HLA ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL FEATURE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEVER; HISTOCOMPATIBILITY; HLA SYSTEM; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENETICS; INCIDENCE; MORBIDITY; PATHOPHYSIOLOGY; PLASMA VOLUME; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY;

ACUTE LUNG INJURY; BLOOD TRANSFUSION; FEMALE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGENETICS; MODELS, BIOLOGICAL; REGENERATIVE MEDICINE;

EID: 79958724687     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01713.x     Document Type: Review

References (61)

1. Barnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions. N Y State J Med 1951: 51: 2399-402.
2. Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983: 128: 185-9.
3. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985: 25: 573-7.
4. Williamson LM, Lowe S, Love EM et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999: 319: 16-9.
5. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005: 19: 2-31.
6. Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev 2004: 18: 184-8.
7. Keller-Stanislawski B, Reil A, Günay S, Funk MB. Frequency and severity of transfusion-related acute lung injury - German haemovigilance data (2006-2007). Vox Sang 2010: 98: 70-7.
8. Chapman CE, Stainsby D, Jones H et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009: 49: 440-52.
9. Win N, Chapman CE, Bowles KM et al. How much residual plasma may cause TRALI? Transfus Med 2008: 18: 276-80.
10. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005: 45: 1628-31.
11. Middelburg RA, Van SD, Briet E, Van Der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008: 48: 2167-76.
12. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007: 136: 788-99.
13. Boshkov LK, Silliman CC. Transfusion-related acute lung injury. Blood Ther Med 2004: 4: 85-93.
14. Khan SY, Kelher MR, Heal JM et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006: 108: 2455-62.
15. Silliman CC, Voelkel NF, Allard JD et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest 1998: 101: 1458-67.
16. Ward HN. Pulmonary infiltrates associated with leukoagglutinin transfusion reactions. Ann Intern Med 1970: 73: 689-94.
17. Brittingham TE. Immunologic studies on leukocytes. Vox Sang 1957: 2: 242-8.
18. Thompson JS, Severson CD, Parmely MJ, Marmorstein BL, Simmons A. Pulmonary "hypersensitivity" reactions induced by transfusion of non-HL-A leukoagglutinins. N Engl J Med 1971: 284: 1120-5.
19. Bux J. Nomenclature of granulocyte antigens. Transfusion 1999: 39: 662-3.
20. Bux J. Human neutrophil alloantigens. Vox Sang 2008: 94: 277-85.
21. Greinacher A, Wesche J, Hammer E et al. Characterization of the human neutrophil alloantigen-3a. Nat Med 2010: 16: 45-8.
22. Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008: 95: 313-7.
23. Bux J, Sohn M, Hachmann R, Mueller-Eckhardt C. Quantitation of granulocyte antibodies in sera and determination of their binding sites. Br J Haematol 1992: 82: 20-5.
24. Fleit HB, Wright SD, Unkeless JC. Human neutrophil Fc gamma receptor distribution and structure. Proc Natl Acad Sci U S A 1982: 79: 3275-9.
25. van Leeuwen A, Eernisse JG, van Rood JJ. A new leucocyte group with two alleles: leucocyte group five. Vox Sang 1964: 9: 431-46.
26. Nair TS, Kozma KE, Hoefling NL et al. Identification and characterization of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 72 kDa that is the target of antibody-induced hearing loss. J Neuro Sci 2004: 24: 1772-9.
27. Stroncek DF, Plachta LB, Herr GP, Dalmasso AP. Analysis of the expression of neutrophil-specific antigen NB1: characterization of neutrophils that react with but are not agglutinated by anti-NB1. Transfusion 1993: 33: 656-60.
28. Lima J, Reddy VV, Marques MB. Transfusion medicine illustrated. Systemic neutrophilic aggregates in transfusion-related acute lung injury. Transfusion 2010: 50: 1427-8.
29. Dykes A, Smallwood D, Kotsimbos T, Street A. Transfusion-related acute lung injury (Trali) in a patient with a single lung transplant. Br J Haematol 2000: 109: 674-6.
30. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion 1999: 39: 103-6.
31. Maslanka K, Michur H, Zupanska B, Uhrynowska M, Nowak J. Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang 2007: 92: 247-9.
32. Triulzi DJ, Kleinman S, Kakaiya RM et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009: 49:1825-35.
33. Kao KJ, Scornik JC, Riley WJ, McQueen CF. Association between HLA phenotype and HLA concentration in plasma or platelets. Hum Immunol 1988: 21: 115-24.
34. Kopko PM, Mackenzie MR, Paglieroni TG, Muto KN, Holland PV. Can HLA class II antibodies cause TRALI? Transfusion 1999: 39: 58S.
35. Kopko PM, Popovsky MA, Mackenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001: 41: 1244-8.
36. Lydaki E, Bolonake E, Nikoloudi E, Chalkiadakis E, Iniotaki-Theodoraki A. HLA class II antibodies in transfusion-related acute lung injury (TRALI). A case report. Transfus Apheresis Sci 2005: 33: 155-9.
37. Sachs UJ, Wasel W, Bayat B et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood 2011: 117: 669-77.
38. Seeger W, Schneider U, Kreusler B et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood 1990: 76: 1438-44.
39. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006: 116: 1615-23.
40. Sachs UJH, Hattar K, Weissmann N et al. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood 2006: 107: 1217-9.
41. Flesch BK, Neppert J. Transfusion-related acute lung injury caused by human leucocyte antigen class II antibody. Br J Haematol 2002: 116: 673-6.
42. Takahashi D, Fujihara M, Azuma H et al. Stimulation of human neutrophils with sera containing HLA class I alloantibody causes preferential degranulation of azurophilic granules and secretory vesicles. Vox Sang 2010: 98: 560-6.
43. Yasui K, Furuta RA, Matsuyama N et al. Possible involvement of heparin-binding protein in transfusion-related acute lung injury. Transfusion 2008: 48: 978-87.
44. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009: 119: 3450-61.
45. Spertini O, Luscinskas FW, Kansas GS et al. Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J Immunol 1991: 147: 2565-73.
46. Silliman CC. Transfusion-related acute lung injury. Transfus Med Rev 1999: 13: 177-86.
47. Dooren MC, Ouwehand WH, Verhoeven AJ, von dem Borne AEG Kr, Kuijpers RWAM. Adult respiratory distress syndrome after experimental intravenous γ-globulin concentrate and monocyte-reactive IgG antibodies. Lancet 1998: 352: 1601-2.
48. Varela M, Mas A, Nogues N, Escorsell A, Mazzara R, Lozano M. TRALI associated with HLA class II antibodies. Transfusion 2002: 42: 1102.
49. Win N, Brown C, Navarrete C. TRALI associated with HLA class II antibodies. Transfusion 2003: 43: 545-6.
50. Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV. TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs. Transfusion 2003: 43: 177-84.
51. Wakamoto S, Fujihara M, Sakagawa H et al. Endothelial permeability is increased by the supernatant of peripheral blood mononuclear cells stimulated with HLA class II antibody. Transfusion 2008: 48: 2060-8.
52. Nishimura M, Hashimoto S, Takanashi M, Okazaki H, Satake M, Nakajima K. Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transfus Med 2007: 17: 129-34.
53. Nishimura M, Hashimoto S, Satake M, Okazaki H, Tadokoro K. Interference with TRALI-causing anti-HLA DR alloantibody induction of human pulmonary microvascular endothelial cell injury by purified soluble HLA DR. Vox Sang 2007: 93: 78-82.
54. Kleinman S. A perspective on transfusion-related acute lung injury two years after the Canadian Consensus Conference. Transfusion 2006: 46: 1465-8.
55. Eder AF, Herron RM Jr, Strupp A et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010: 50: 1732-42.
56. Engelfriet CP, Reesink HW. Measures to prevent TRALI. Vox Sang 2007: 92: 258-77.
57. Kakaiya RM, Triulzi DJ, Wright DJ et al. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion 2010: 50: 1328-34.
58. Vassallo RR, Hsu S, Einarson M, Barone J, Brodsky J, Moroff G. A comparison of two robotic platforms to screen plateletpheresis donors for HLA antibodies as part of a transfusion-related acute lung injury mitigation strategy. Transfusion 2010: 50: 1766-77.
59. ISBT Working Party on Granulocyte Immunobiology, Bierling P, Bux J et al. Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury. Vox Sang 2009: 96: 266-9.
60. Fadeyi E, Adams S, Peterson B et al. Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion 2008: 48: 1174-9.
61. Makar RS, Saidman SL, Stowell CP, Lee H, Powers A. Analysis of cutoffs for screening sensitized blood donors for HLA alloantibodies using a cytometric microbead assay. Transfusion 2011: 51: 166-74.